Columbia Laboratories to Hold Conference Call on Third Quarter 2003 Financial Results

Columbia Laboratories to Hold Conference Call on Third Quarter 2003 Financial
Results 


LIVINGSTON, N.J., Nov. 7  /PRNewswire-FirstCall/ -- Columbia Laboratories  will
be holding a conference call on November 12, 2003 at 8:30 AM ET to review third
quarter 2003 financial results.  Fred Wilkinson, Columbia's chairman, president
and chief executive officer, and David Weinberg, Columbia's chief financial
officer, will review new corporate and clinical developments.

The U.S./Canada dial-in number is 877-407-8031.  The international dial-in
number is 201-689-8031.  A recording of the conference call will be available
two hours after completion, and will be available until November 19, 2003 at
11:59 PM ET at 877-660-6853 (U.S.) and 201-612-7415.  The conference account
number is 1628, and the ID number is 81831.

The call will be webcast on the Columbia Laboratories Web site, and will be
available until February 12, 2004 at 11:59 PM ET at
http://www.columbialabs.com/

About Columbia Laboratories

Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company
dedicated to research and development of women's health care and endocrinology
products, including those intended to treat infertility, dysmenorrhea,
endometriosis and hormonal deficiencies. Columbia has introduced Striant(TM)
(testosterone buccal system) for treatment of hypogonadism in men. Columbia's
products primarily utilize the Company's patented Bioadhesive Delivery System
(BDS) technology. For more information, please visit
http://www.columbialabs.com/.

This press release contains statements that constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Those statements include statements regarding the intent, belief or current
expectations of the company and its management team. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results may
differ materially from those projected in the forward-looking statements. Such
risks and uncertainties include, among other things, the successful marketing of
existing products, including Striant(TM) (testosterone buccal system),
Prochieve(R) 8% (progesterone gel), Prochieve(R) 4% (progesterone gel),
RepHresh(R) Vaginal Gel, and Advantage-S(R) Contraceptive Gel; timely and
successful development of new products; timely and successful completion of
clinical studies; success in obtaining acceptance and approval of new products
by the FDA and international regulatory agencies; and competitive economic and
regulatory factors in the pharmaceutical and health care industry; general
economic conditions; and other risks and uncertainties that may be detailed,
from time-to-time, in Columbia's reports filed with the Securities and Exchange
Commission. 

DATASOURCE: Columbia Laboratories, Inc.



CONTACT:  Investors - Ritu Baral of The Trout Group, [phone],

ext. 25, for Columbia Laboratories, Inc.; James Apostolakis, Vice Chairman,

[phone], or David Weinberg, Chief Financial Officer, [phone],

both of Columbia Laboratories, Inc.



Web site:  http://www.columbialabs.com/ 

Copyright